{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:22:33Z","timestamp":1794950553497,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:00:00Z","timestamp":1794873600000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gastrohep.2026.502871","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:45:02Z","timestamp":1791416702000},"page":"502871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-\u03b1 as first- and second-line biologic treatment in Crohn's disease"],"prefix":"10.1016","author":[{"given":"Jos\u00e9 Fernando","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Guti\u00e9rrez-Casbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Riestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Herrera de Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Vera-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Mart\u00ednez-Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Tagarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Letosa Abi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2026.502871_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0150","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0155","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211010668","article-title":"Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience","volume":"14","author":"Macaluso","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0165","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/jcm10132885","article-title":"Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study","volume":"10","author":"Chaparro","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0170","doi-asserted-by":"crossref","first-page":"e00481","DOI":"10.14309\/ctg.0000000000000481","article-title":"Incidence trends of inflammatory bowel disease in a southern European country: a mirror of the western world?","volume":"13","author":"Santiago","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn's & Colitis foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0185","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231222344","article-title":"Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis","volume":"17","author":"Brunet-Mas","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0190","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","article-title":"Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in Spain: a systematic review","volume":"40","author":"Barreiro-de Acosta","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0195","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/MIB.0000000000000399","article-title":"Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact","volume":"21","author":"Zand","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0200","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0205","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.gastrohep.2026.502871_bib0215","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"Alpha4 integrins as therapeutic targets in autoimmune disease","volume":"348","author":"von Andrian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0230","article-title":"Entyvio\u00ae (vedolizumab) \u2013 summary of product characteristics","year":"2023","journal-title":"EMA"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0235","article-title":"Entyvio\u00ae 300mg powder for concentrate for solution for infusion \u2013 summary of product characteristics","year":"2023","journal-title":"EMA"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0245","series-title":"Takeda Receives European Commission Marketing Authorisation for Entyvio\u00ae(vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease","author":"Takeda","year":"2014"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0250","series-title":"SAS Software \u2013 SAS Analytics Software version 9.4","author":"SAS","year":"2023"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0255","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/ibd\/izy155","article-title":"Effectiveness and safety of vedolizumab in anti-TNF-Na\u00efve patients with inflammatory bowel disease \u2013 a multicenter retrospective European study","volume":"24","author":"Kopylov","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0260","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ibd\/izad138","article-title":"Real-world effectiveness of vedolizumab vs anti-TNF in biologic-na\u00efve Crohn's disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-study","volume":"30","author":"Bokemeyer","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0265","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-Na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0270","doi-asserted-by":"crossref","first-page":"480","DOI":"10.5946\/ce.2022.108","article-title":"Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice","volume":"55","author":"Kim","year":"2022","journal-title":"Clin Endosc"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0275","article-title":"Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohn's Colitis 360"},{"key":"10.1016\/j.gastrohep.2026.502871_bib0280","first-page":"608","article-title":"The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab","volume":"115","author":"Navajas Hern\u00e1ndez","year":"2023","journal-title":"Rev Esp Enferm Dig"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570526009611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570526009611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:56:10Z","timestamp":1794948970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570526009611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0210570526009611"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2026.502871","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-\u03b1 as first- and second-line biologic treatment in Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2026.502871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502871"}}